CA21154 - Translational control in Cancer European Network (TRANSLACORE)
TRANSLACORE
Understanding the importance of protein synthesis dysregulation in cancer
CA21154 - Translational control in Cancer European Network (TRANSLACORE)
Translacore
Join the Network
CA21154 - Translational control in Cancer European Network (TRANSLACORE)
Map of TRANSLACORE Team Members Across Europe
Our aims
Philosophy
Understanding the importance of protein synthesis dysregulation in cancer
Objectives
Promoting multiple cross-disciplinary research partnerships
Capacity Building
Strengthen scientific interactions among experts across Europe with complementary skills
State of the art
Dysregulated translation in cancer exposes vulnerabilities that are amenable to targeted therapies.
Upcoming events in Translacore
View all events
People involved in Translacore
View all members
You might also like
Translacore open database
PhD position on the role of ribosomal protein defects in cancer pathogenesis
The laboratory for Disease Mechanisms in Cancer (KU Leuven, Belgium, www.LDMC.be) is looking for a motivated PhD researcher. Whereas a lot of research on disease biology and cancer has focused on dysregulated gene expression at the level of transcription, our lab has built up a strong research track on disease mechanisms due to defective protein translation, for instance by mutations in ribosomal proteins. You can apply for this job no later than July 31, 2025.
Job offer in molecular biology and structural biology for PhD student
Job offer in molecular biology and structural biology. PhD-STUDENT SCHOLARSHIP (for a period of 25 months, with the possibility of extension by 1 year or more) in the field of biochemistry, biophysics and structural biology at the Department of Molecular Biology, University of Maria Curie-Skłodowska, Lublin, Poland
Biotechnology Engineer in Oncology
The position is part of an INCa-funded project to study the impact of chemotherapies on protein synthesis and tumor cell plasticity. It is located at the Centre de Recherche en Cancérologie de Lyon (CRCL) (directed by P Mehlen), an internationally renowned center dedicated to innovative oncology research (www.crcl.fr). The engineer will be integrated into the “Ribosome, Translation and Cancer” team, headed by Dr. Jean-Jacques Diaz. The team explores the role of protein synthesis and ribosomes in tumor pathology. --> Deadline for application, 15 May 2025
